Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives

Brain

Volumn 120, Issue 5, 1997, Pages 865-914

  Hohlfeld, Reinhard ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

Author keywords

Autoimmunity; Biotechnology; Immunotherapy; Multiple sclerosis; T lymphocytes

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; MATRIX METALLOPROTEINASE INHIBITOR; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNITY; BIOTECHNOLOGY; ETIOLOGY; GENE THERAPY; GENETIC ENGINEERING; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; BIOLOGICAL PRODUCTS; HUMANS; IMMUNOTHERAPY; MULTIPLE SCLEROSIS;

EID: 0030989875     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/120.5.865     Document Type: Article

References (413)

1. Abreu SL. Interferon in experimental autoimmune encephalomyelitis (EAE): effects of exogeneous interferon on the antigen-enhanced adoptive transfer of EAE. Int Arch Allergy Appl Immunol 1985; 76: 302-7.
2. Acha-Orbea H, Mitchell DJ, Timmermann L, Wraith DC, Tausch GS, Waldor MK, et al. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell 1988; 54: 263-73.
3. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175: 323-9.
4. Adorini L, Guéry J-C, Rodriguez-Tarduchy G, Trembleau S. Selective immunosuppression. [Review]. Immunol Today 1993; 14: 285-9.
5. Aharoni R, Teitelbaum D, Arnon R, Pun J. Immunomodulation of experimental allergic encephalomyelitis by antibodies to the antigen-Ia complex. Nature 1991; 351: 147-50.
6. Akassoglou K, Probert L, Kontogeorgos G, Kollias G. Astrocyte-specific but not neuron-specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice. J Immunol 1997; 158: 438-45.
7. Al-Sabbagh A, Miller A, Santos LMB, Weiner HL. Antigen-driven tissue-specific suppression following oral tolerance: orally administered myelin basic protein suppresses proteolipid protein-induced experimental autoimmune encephalomyelitis in the SJL mouse. Eur J Immunol 1994; 24: 2104-9.
8. Andersen O, Lycke J, Tollesson PO, Svenningsson A, Runmarker B, Linde AS, et al, Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 1996; 47: 895-900.
9. Antel JP, Becher B, Owens T. Immunotherapy for multiple sclerosis: from theory to practice. [Review]. Nature Med 1996; 2: 1074-5.
10. Archelos JJ, Jung S, Mäurer M, Schmied M, Lassmann H, Tamatani T, et al. Inhibition of experimental autoimmune encephalomyelitis by an antibody to the intercellular adhesion molecule ICAM-1. Ann Neurol 1993; 34: 145-54.
11. Arend WP. Interleukin-1 receptor antagonist. [Review]. Adv Immunol 1993; 54: 167-227.
12. Arima T, Rehman A, Hickey WF, Flye MW. Inhibition by CTLA4Ig of experimental allergic encephalomyelitis. J Immunol 1996; 156: 4916-24.
13. Arimilli S, Mumm JB, Nag B. Antigen-specific apoptosis in immortalized T cells by soluble MHC class II-peptide complexes. Immunol Cell Biol 1996; 74: 96-104.
14. Arnason BGW. Interferon beta in multiple sclerosis. [Review]. Clin Immunol Immunopathol 1996; 81: 1-11.
15. Arnason BGW, Reder AT. Interferons and multiple sclerosis. [Review]. Clin Neuropharmacol 1994; 17: 495-547.
16. Arnon R. The development of Cop-1 (Copaxone), an innovative drug for the treatment of multiple sclerosis. [Review]. Immunol Lett 1996; 50: 1-15.
17. Askari FK, McDonnell WM. Molecular medicine: antisense-oligonucleotide therapy. [Review]. N Engl J Med 1996; 334: 316-8.
18. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis [see comments]. Science 1995; 270: 286-90. Comment in: Science 1995; 270: 232-3.
19. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis [see comments]. Science 1995; 270: 286-90. Comment in: Science 1995; 270: 232-3.
20. Baker D, Butler D, Scallon BJ, O'Neill JK, Turk JL, Feldrnann M. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 1994; 24: 2040-8.
21. Barkhof F, Scheltens P, Frequin STFM, Nauta JJP, Tas MW, Valk J, et al. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR Am J Radiol 1992; 159: 1041-7.
22. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA Jr. Surface expression of α4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 1993; 177: 57-68.
23. Bauer J, Wekerle H, Lassmann H. Apoptosis in brain-specific autoimmune disease. [Review]. Curr Opin Immunol 1995; 7: 839-43.
24. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. [Review]. N Engl J Med 1996; 334: 1717-25.
25. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988; 78:318-23.
26. Ben-Nun A, Cohen IR. Vaccination against autoimmune encephalomyelitis (EAE): attenuated autoimmune T lymphocytes confer resistance to induction of active EAE but not to EAE mediated by the intact T lymphocyte line. Eur J Immunol 1981; 11:949-52.
27. Ben-Nun A, Wekerle H, Cohen IR. Vaccination against autoimmune with T-lymphocyte line cells reactive against myelin basic protein. Nature 1981; 292: 60-1.
28. Ben-Nun A, Mendel I, Bakimer R, Fridkis-Hareli M, Teitelbaum D, Arnon R, et al. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease. J Neurol 1996; 243 Suppl 1: S14-S22.
29. Bendtzen K, Hansen MB, Ross C, Poulsen LK, Svenson M. Cytokines and autoantibodies to cytokines. [Review]. Stem Cells (Dayt) 1995; 13: 206-22.
30. Bennett TA, Lynam EB, Sklar LA, Rogelj S. Hydroxamate-based metalloprotease inhibitor blocks shedding of L-selectin adhesion molecule from leukocytes. Functional consequences for neutrophil aggregation. J Immunol 1996; 156: 3093-7.
31. Berman JW, Guida MP, Warren J, Amat J, Brosnan CF. Localization of monocyte chemoattractant peptide-1 expression in the central nervous system in experimental autoimmune encephalomyelitis and trauma in the rat. J Immunol 1996; 156: 3017-23.
32. Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. [Review]. N Engl J Med 1987; 316: 379-385.
33. Beutler B, Cerami A. The biology of cachectin/TNF-a primary mediator of the host response. [Review]. Annu Rev Immunol 1989; 7: 625-55.
34. Blanas E, Carbone FR, Allison J, Miller JFAP, Heath WR. Induction of autoimmune diabetes by oral administration of autoantigen. Science 1996; 274: 1707-9.
35. Bö L, Dawson TM, Wesselingh S, Mörk S, Choi S, Kong PA, et al. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 1994; 36: 778-86.
36. Bokoch GM. Chemoattractant signaling and leukocyte activation. [Review]. Blood 1995; 86: 1649-60.
37. Bornstein MB, Miller A, Slagle S, Weitzman M, Crystal H, Drexler E, et al. A pilot trial of Cop-1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987; 317: 408-14.
38. Bornstein MB, Miller A, Slagle S, Weitzman M, Drexler E, Keilson M, et al. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop-1 in chronic progressive multiple sclerosis. Neurology 1991; 41: 533-9.
39. Bourdette DN, Whitham RH, Chou YK, Morrison WJ, Atherton J, Kenny C, et al. Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic Vβ5.2 and Vβ6.1 CDR2 peptides [published erratum apperars in J Immunol 1994; 153: 910]. J Immunol 1994; 152: 2510-9.
40. Bright JJ, Topham DJ, Nag B, Lodge PA, Sriram S. Vaccination with peptides from MHC class II beta chain hypervariable region causes allele-specific suppression of EAE. J Neuroimmunol 1996; 67: 119-24.
41. Brocke S, Gaur A, Piercy C, Gautam A, Gijbels K, Fathman CG, et al. Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen. Nature 1993; 365: 642-4.
42. Brocke S, Veromaa T, Weissman IL, Gijbels K, Steinman L. Infection and multiple sclerosis: a possible role for superantigens? [Review]. Trends Microbiol 1994; 2: 250-4.
43. Brocke S, Gijbels K, Allegretta M, Ferber I, Piercy C, Blankenstein T, et al. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 1996; 379: 343-6.
44. Brod SA, Khan M. Oral administration of interferon-α is superior to subcutaneous administration of interferon-α in the suppression of chronic relapsing experimental autoimmune encephalomyelitis. J Autoimmun 1996; 9: 11-20.
45. Brod SA, Scott M, Burns DK, Phillips JT. Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of type 1 interferons. J Interferon Cytokine Res 1995; 15: 115-22.
46. Brosnan CF, Raine CS. Mechanisms of immune injury in multiple sclerosis. [Review]. Brain Pathol 1996; 6: 243-57.
47. Brosnan CF, Selmaj K, Raine CS. Hypothesis: a role for tumor necrosis factor in immune-mediated demyelination and its relevance to multiple sclerosis. J Neuroimmunol 1988; 18: 87-94.
48. Brosnan CF, Battistini L, Gao YL, Raine CS, Aquino DA. Heat shock proteins and multiple sclerosis: a review. [Review]. J Neuropathol Exp Neurol 1996; 55: 389-402.
49. Burger D, Chicheportiche R, Gin JG, Dayer J-M. The inhibitory activity of human IL-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest 1995; 96: 38-41.
50. Burns J, Rosenzweig A, Zweiman B, Lisak RP. Isolation of myelin basic protein-reactive T-cell lines from normal human blood. Cell Immunol 1983; 81: 435-40.
51. Burns FR, Li XB, Shen N, Offner H, Chou YK, Vandenbark AA, et al. Both rat and mouse T cell receptors specific for the encephalitogenic determinant of myelin basic protein use similar Vα and Vβ chain genes even though the major histocompatibility complex and encephalitogenic determinants being recognized are different. J Exp Med 1989; 169: 27-39.
52. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. [Review]. Science 1996; 272: 60-6.
53. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions [see comments]. Ann Neurol 1995; 37: 424-35. Comment in: Ann Neurol 1995; 37: 419-21.
54. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions [see comments]. Ann Neurol 1995; 37: 424-35. Comment in: Ann Neurol 1995; 37: 419-21.
55. Cannella B, Gao Y-L, Brosnan C, Raine CS. IL-10 fails to abrogate experimental autoimmune encephalomyelitis. J Neurosci Res 1996; 45: 735-46.
56. Cash E, Minty A, Ferrara P, Caput D, Fradelizi D, Rott O. Macrophage-inactivating IL-13 suppresses experimental autoimmune encephalomyelitis in rats. J Immunol 1994; 153: 4258-67.
57. Chandler S, Miller KM, Clements JM, Lury J, Corkill D, Anthony DCC, et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. [Review]. J Neuroimmunol 1997; 72: 155-61.
58. Chen Y, Kuchroo VK, Inobe J-I, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994; 265: 1-237-40.
59. Chernoff AE, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, et al. A randomized controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 1995; 154: 5492-9.
60. Chiang C-S, Powell HC, Gold LH, Samimi A, Campbell IL. Macrophage/microglial-mediated primary demyelination and motor disease induced by the central nervous system production of interleukin-3 in transgenic mice. J Clin Invest 1996; 97: 1512-24.
61. Chluba J, Steeg C, Becker A, Wekerle H, Epplen JT. T cell receptor β chain usage in myelin basic protein-specific rat T lymphocytes. Eur J Immunol 1989; 19: 279-84.
62. Chofflon M, Juillard C, Juillard P, Gauthier G, Grau GE. Tumor necrosis factor a production as a possible predictor of relapse in patients with multiple sclerosis. Eur Cytokine Netw 1992; 3: 523-31.
63. Choi DW. Nitric oxide: foe or friend to the injured brain? [Comment]. [Review]. Proc Natl Acad Sci USA 1993; 90: 9741-3. Comment on: Proc Natl Acad Sci USA 1993; 90: 9808-12.
64. Choi DW. Nitric oxide: foe or friend to the injured brain? [Comment]. [Review]. Proc Natl Acad Sci USA 1993; 90: 9741-3. Comment on: Proc Natl Acad Sci USA 1993; 90: 9808-12.
65. Chou YK, Morrison WJ, Weinberg AD, Dedrick R, Whitham R, Bourdette DN, et al. Immunity to TCR peptides in multiple sclerosis. II. T cell recognition of Vβ5.2 and Vβ6.1 CDR2 peptides [published erratum appears in J Immunol 1994; 153: 910]. J Immunol 1994; 152: 2520-9.
66. Chunduru SK, Sutherland RM, Stewart GA, Doms RW, Paterson Y. Exploitation of the Vβ8.2 T cell receptor in protection against experimental autoimmune encephalomyelitis using a live vaccinia virus vector. J Immunol 1996; 156: 4940-5.
67. Cleveland JL, Ihle JN. Contenders in FasL/TNF death signaling. [Review]. Cell 1995; 81: 479-82.
68. Cohen IR. The cognitive paradigm and the immunological homunculus. [Review]. Immunol Today 1992; 13: 490-4.
69. Compston A. Brain repair. [Review]. J Intern Med 1995; 237: 127-34.
70. Compston A, Scolding N, Wren D, Noble M. The pathogenesis of demyelinating disease: insights from cell biology. [Review]. Trends Neurosci 1991; 14: 175-82.
71. Cousens LP, Orange JS, Su HC, Biron CA. Interferon-α/β inhibition of interleukin 12 and interferon-γ production in vitro and endogenously during viral infection. Proc Natl Acad Sci USA 1997; 94: 634-9.
72. Crisi GM, Santambrogio L, Hochwald GM, Smith SR, Carlino JA, Thorbecke GJ. Staphylococcal enterotoxin B and tumor-necrosis factor-a induced relapses of experimental allergic encephalomyelitis: Protection by transforming growth factor-β and interleukin-10. Eur J Immunol 1995; 25: 3035-40.
73. Crispe IN. Fatal interactions: Fas-induced apoptosis of mature T cells. [Review]. Immunity 1994; 1: 347-9.
74. Critchfield JM, Racke MK, Zuñiga-Pflücker JC, Cannella B, Raine CS, Goverman J, et al. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 1994; 263:1139-43.
75. Cross AH, Cannella B, Brosnan CF, Raine CS. Hypothesis: antigen-specific T cells prime central nervous system endothelium for recruitment of nonspecific inflammatory cells to effect autoimmune demyelination. [Review]. J Neuroimmunol 1991; 33: 237-44.
76. Cross AH, Girard TJ, Giacoletto KS, Evans RJ, Keeling RM, Lin RF, et al. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation [see comments]. J Clin Invest 1995; 95: 2783-9. Comment in: J Clin Invest 1995; 95: 2429-30.
77. Cross AH, Girard TJ, Giacoletto KS, Evans RJ, Keeling RM, Lin RF, et al. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation [see comments]. J Clin Invest 1995; 95: 2783-9. Comment in: J Clin Invest 1995; 95: 2429-30.
78. Cuzner ML, Gveric D, Strand C, Loughlin AJ, Paemen L, Opdenakker G, et al. The expression of tissue-type plasminogen-activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol 1996; 55: 1194-204.
79. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. [Review]. Science 1994; 264: 1415-21.
80. Davis LS, Kavanaugh AF, Nichols LA, Lipsky PE. Induction of persistent T cell hyporesponsiveness in vivo by monoclonal antibody to ICAM-1 in patients with rheumatoid arthritis. J Immunol 1995; 154: 3525-37.
81. Davodeau F, Peyrat M-A, Romagné F, Necker A, Hallet M-M, Vié H, et al. Dual T cell receptor β chain expression on human T lymphocytes. J Exp Med 1995; 181: 1391-8.
82. De Groot CJA, Ruuls SR, Theeuwes JWM, Dijkstra CD, Van der Valk P. Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions. J Neuropathol Exp Neurol 1997; 56: 10-20.
83. De Kruif J, Van de Vuurst de Vries A-R, Cilenti L, Boel E, van Ewijk W, Logtenberg T. New perspectives on recombinant human antibodies. [Review]. Immunol Today 1996; 17: 453-5.
84. De Simone R, Giampaolo A, Giometto B, Gallo P, Levi G, Peschle C, et al. The costimulatory molecule B7 is expressed on human microglia in culture and in multiple sclerosis acute lesions. J Neuropathol Exp Neurol 1995; 54: 175-87.
85. Del Prete G, Maggi E, Romagnani S. Human Th1 and Th2 cells: functional properties, mechanisms of regulation and role in disease. [Review]. Lab Invest 1994; 70: 299-306.
86. Dinarello CA. Biologic basis for interleukin-1 in disease. [Review]. Blood 1996; 87: 2095-147.
87. Dinarello CA, Thompson RC. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. [Review]. Immunol Today 1991; 12: 404-10.
88. Duchosal MA, Rothermel AL, McConahey PJ, Dixon FJ, Altieri DC. In vivo immunosuppression by targeting a novel protease receptor. Nature 1996; 380: 352-6.
89. Duncan ID. Glial cell transplantation and remyelination of the central nervous system. [Review]. Neuropathol Appl Neurobiol 1996; 22: 87-100.
90. Durelli L, Bongioannj MR, Cavallo R, Ferrero B, Fern R, Ferrio MF, et al. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994; 44: 406-13.
91. Durelli L, Bongioanni MR, Ferrero B, Fern R, Imperiale D, Bradac GB, et al. Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatment. Neurology 1996; 47: 123-9.
92. Ebers GC. Treatment of multiple sclerosis. [Review]. Lancet 1994; 343: 275-80.
93. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet 1994a; 344: 1105-10.
94. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994b; 344: 1125-7.
95. Elliott EA, McFarland HI, Nye SH, Cofiell R, Wilson TM, Wilkins JA, et al. Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein. J Clin Invest 1996; 98: 1602-12.
96. Fabry Z, Raine CS, Hart MN. Nervous tissue as an immune compartment: the dialect of the immune response in the CNS. [Review]. Immunol Today 1994; 15: 218-24.
97. Fabry Z, Topham DJ, Fee D, Herlein J, Carlino JA, Hart MN, et al. TGF-β2 decreases migration of lymphocytes in vitro and homing of cells into the central nervous system in vivo. J Immunol 1995; 155: 325-32.
98. Farrar MA, Schreiber RD. The molecular cell biology of interferon-γ and its receptor. [Review]. Annu Rev Immunol 1993; 11: 571-611.
99. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B, for the Austrian Immunoglobulin in Multiple Sclerosis Study Group. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997; 349: 589-93.
100. Fierlbeck G, Schreiner T, Schaber B, Walser A, Rassner G. Neutralizing interferon β antibodies in melanoma patients treated with recombinant and natural interferon β. Cancer Immunol Immunother 1994; 39: 263-8.
101. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996; 334: 1697-702.
102. Fleischer B. Superantigens. [Review]. APMIS 1994; 102: 3-12.
103. Fontana A, Fierz W, Wekerle H. Astrocytes present myelin basic protein to encephalitogenic T cell lines. Nature 1984; 307: 273-6.
104. Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ. Immune regulation by CD40 and its ligand gp39. [Review]. Annu Rev Immunol 1996; 14: 591-617.
105. Francisco JA, Kiener PA, Moran-Davis P, Ledbetter JA, Siegall CP. Cytpkine activation sensitizes human monacytic and endothelial cells to the cytotoxic effects of an anti-CD40 immunotoxin. J Immunol 1996; 157: 1652-8.
106. Franco A, Southwood S, Arrhenius T, Kuchroo VK, Grey HM, Seite A, et al. T cell receptor antagonist peptides are highly effective inhibitors of experimental allergic encephalomyelitis. Eur J Immunol 1994; 24: 940-6.
107. Franklin RJM. Reconstructing myelin-deficient environments in the CNS by glial cell transplantation. [Review]. Semin Neurosci 1993; 5: 443-51.
108. Friedmann T. Human gene therapy-an immature genie, but certainly out of the bottle. [Review]. Nat Med 1996; 2: 144-7.
109. Furie MB, Randolph GJ. Chemokines and tissue injury. [Review]. Am J Pathol 1995; 146: 1287-301.
110. Garboczi DN, Ghosh P, Utz U, Fan QR, Biddison WE, Wiley DC. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 1996; 384: 134-41.
111. Garcia KC, Degano M, Stanfield RL, Brunmark A, Jackson MR, Peterson PA, et al. The αβ T cell receptor structure at 2.5 Å and its orientation in the TCR-MHC complex. Science 1996; 274: 209-19.
112. Gaur A, Wiers B, Liu A, Rothbard J, Fathman CG. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science 1992; 258: 1491-4.
113. Gautam AM. Self and non-self peptides treat autoimmune encephalomyelitis: T cell anergy or competition for major histocompatibility complex class II binding? Eur J Immunol 1995; 25: 2059-63.
114. Gearing AJN, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, et al. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 1994; 370: 555-7.
115. Genain CP, Lee-Parritz D, Nguyen M-H, Massacesi L, Joshi N, Ferrante R, et al. In healthy primates, circulating autoreactive T cells mediate autoimmune disease [see comments]. J Clin Invest 1994; 94: 1339-45. Comment in: J Clin Invest 1994; 94: 921-2.
116. Genain CP, Lee-Parritz D, Nguyen M-H, Massacesi L, Joshi N, Ferrante R, et al. In healthy primates, circulating autoreactive T cells mediate autoimmune disease [see comments]. J Clin Invest 1994; 94: 1339-45. Comment in: J Clin Invest 1994; 94: 921-2.
117. Genain CP, Nguyen M-H, Letvin NL, Pearl R, Davis RL, Adelman M, et al. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J Clin Invest 1995a; 96: 2966-74.
118. Genain CP, Roberts T, Davis RL, Nguyen M-H, Uccelli A, Faulds D, et al. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc Natl Acad Sci USA 1995b; 92: 3601-05.
119. Genain CP, Abel K, Belmar N, Villinger F, Rosenberg DP, Linington C, et al. Late complications of immune deviation therapy in a nonhuman primate. Science 1996; 274: 2054-7.
120. Gijbels K. A study on the role of interleukin-6 and matrix metalloproteinases in inflammatory demyelinating disorders in the central nervous system [PhD thesis]. Louvain: University of Louvain, 1995.
121. Gijbels K, Galardy RE, Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 1994; 94: 2177-82.
122. Gilat D, Cahalon L, Hershkoviz R, Lider O. interplay of T cells and cytokines in the context of enzymatically modified extracellular matrix. [Review]. Immunol Today 1996; 17: 16-20.
123. Giovannoni G, Thorpe JW, Kidd D, Kendall BE, Moseley IF, Thompson AJ, et al. Soluble E-seleetin in multiple sclerosis:Raised concentrations in patients with primary progressive disease. J Neurol Neurosurg Psychiatry 1996; 60: 20-6.
124. Glabinski AR, Tani M, Stricter RM, Tuohy VK, Ransohoff RM. Synchronous synthesis of α- and β-chemoklnes by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis. Am J Pathol 1997; 150: 617-30.
125. Godiska R, Chantry D, Dietsch GN, Gray PW, Chemokine expression in murine experimental allergic encephalomyelitis. J Neuroimmunol 1995; 58: 167-76.
126. Goetzl EJ, Banda MJ, Leppert D. Matrix metalloproteinases in immunity. [Review]. J Immunol 1996; 156: 1-4.
127. Gonzalo JA, Gonzalez-Garcia A, Kalland T, Hedlund G, Martinez C, Kroemer G. Linomide, a novel immunomodulator that prevents death in four models of septic shock. Eur J Immunol 1993; 23: 2372-4.
128. Gordon EJ, Myers KJ, Dougherty JP, Rosen H, Ron Y. Both anti-CD11a (LFA-1) and anti-CD11b (MAC-1) therapy delay the onset and diminish the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol 1995; 62: 153-60.
129. + T-cell responses. [Review]. Immunol Today 1996; 17: 410-4.
130. Grewal IS, Foellmer HG, Grewal KD, Xu J, Hardardottir F, Baron JL, et al. Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science 1996; 273: 1864-7.
131. + T cells [see comments]. J Exp Med 1996; 184: 19-29. Comment in: J Exp Med 1996; 184: 1-8.
132. + T cells [see comments]. J Exp Med 1996; 184: 19-29. Comment in: J Exp Med 1996; 184: 1-8.
133. Hafler DA, Weiner HL. Immunologie mechanisms and therapy in multiple sclerosis. [Review]. Immunol Rev 1995; 144: 75-07.
134. Hafler DA, Ritz J, Schlossman SF, Weiner HL. Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. Immunosuppressive effects and human anti-mouse responses. J Immunol 1988; 141: 131-8.
135. Hafler DA, Saadeh MG, Kuchroo VK, Milford E, Steinman L. TCR usage in human and experimental demyelinating disease. [Review]. Immunol Today 1996; 17: 152-9.
136. Hall GL, Compston A, Scolding NJ. Beta-interferon and multiple sclerosis. [Review]. Trends Neurosci 1997; 20: 63-7.
137. Hartung H-P, Archelos JJ, Zielasek J, Gold R, Koltzenburg M, Reiners K-H, et al. Circulating adhesion molecules and inflammatory mediators in demyelination: a review. [Review]. Neurology 1995; 45 (6 Suppl 6): S22-32.
138. Hauser SL. Prevention strategies for multiple sclerosis. [Review]. Ann Neurol 1994; 36 Suppl: S157-62.
139. Heaney ML, Golde DW, Soluble cytokine receptors. [Review]. Blood 1996; 87: 847-57.
140. Heller RA, Krönke M, Tumor necrosis factor receptor-mediated signaling pathways. [Review]. J Cell Biol 1994; 126: 5-9.
141. Hemler ME, VLA proteins in the integrin family: structures, functions, and their role on leukocytes. [Review]. Annu Rev Immunol 1990; 8: 365-400.
142. Hewson AK, Smith T, Leonard JP, Cuzner ML. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproternase inhibitor Ro31-9790. Inflamm Res 1995; 44: 345-9.
143. Mickey WF, Gonatas NK, Kimura H, Wilson DB, Identification and quantitation of T lymphocyte subsets found in the spinal cord of the Lewis rat during acute experimental allergic encephalomyelitis. J Immunol 1983; 131: 2805-9.
144. Hodgkin PD, Basten A. B cell activation, tolerance and antigen-presenting function. [Review]. Curr Opin Immunol 1995; 7: 121-9.
145. Hogg N, Berlin C. Structure and function of adhesion receptors in leukocyte trafficking. [Review]. Immunol Today 1995; 16: 327-30.
146. Hohlfeld R. Neurological autoimmune disease and the trimolecular complex of T-lymphocytes. [Review]. Ann Neurol 1989; 25: 531-8.
147. Hohlfeld R, Meinl E, Weber F, Zipp F, Schmidt S, Sotgiu S, et al. The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosis. [Review]. Neurology 1995; 45 (6 Suppl 6): S33-8.
148. Hortelano S, Diaz-Guerra MJM, Gonzalez-Garcia A, Leonardo E, Gamallo C, Bosca L, et al. Linomide administration to mice attenuates the induction of nitric oxide synthase elicited by lipopolysaccharide-activated macrophages and prevents nephritis in MRL/Mp-lpr/lpr mice. J Immunol 1997; 158: 1402-8.
149. Howell MD, Winters ST, Olee T, Powell HC, Carlo DJ, Brostoff SW. Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides [published erratum appears in Science 1990; 247: 1167]. Science 1989; 246: 668-70.
150. Huitinga I, Damoiseaux JGMC, Döpp EA, Dijkstra CD. Treatment with anti-CR3 antibodies ED7 and ED8 suppresses xperimental allergic encephalomyelitis in Lewis rats. Eur J Immunol 1993; 23: 709-15.
151. Hulkower K, Brosnan CF, Aquino DA, Cammer W, Kulshrestha S, Guida MP, et al. Expression of CSF-1, c-fms, and MCP-1 in the central nervous system of rats with experimental allergic encephalomyelitis. J Immunol 1993; 150: 2525-33.
152. Hurwitz AA, Sullivan TJ, Krummel MF, Sobel RA, Allison JP. Specific-blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J Neuroimmunol 1997; 73: 57-62.
153. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial [see comments]. Neurology 1993; 43: 655-61. Comment in: Neurology 1993; 43: 641-3.
154. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial [see comments]. Neurology 1993; 43: 655-61. Comment in: Neurology 1993; 43: 641-3.
155. IFNB Multiple Sclerosis Study Group. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 1995; 45: 1277-85.
156. IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 1996; 47: 889-94.
157. Ihle JN. STATs: signal transducers and activators of transcription. [Review]. Cell 1996; 84: 331-4.
158. Imamura K, Suzumura A, Hayashi F, Marunouchi T. Cytokine production by peripheral blood monocytes/macrophages in multiple sclerosis patients. Acta Neurol Scand 1993; 87: 281-5.
159. Imhof BA, Dunon D. Leukocyte migration and adhesion. [Review]. Adv Immunol 1995; 58: 345-416.
160. Inaba K, Kitaura M, Kato T, Watanabe Y, Kawade Y, Muramatsu S. Contrasting effect of α/β and γ interferons on expression of macrophage Ia antigens. J Exp Med 1986; 163: 1030-5.
161. Jäättelä M. Biologic activities and mechanisms of action of tumor necrosis factor-α/cachectin. [Review]. Lab Invest 1991; 64: 724-742.
162. Jacobs L, Johnson KP. A brief history of the use of interferons as treatment of multiple sclerosis. [Review]. Arch Neurol 1994; 51: 1245-52.
163. Jacobs CA, Baker PE, Roux ER, Picha KS, Toivola B, Waugh S, et al. Experimental autoimmune encephalomyelitis is exacerbated by IL-1α and suppressed by soluble IL-1 receptor. J Immunol 1991; 146: 2983-9.
164. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1 a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
165. Jameson BA, McDonnell JM, Marini JC, Korngold R. A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis [see comments]. Nature 1994; 368: 744-6. Comment in: Nature 1994; 368: 692-3, Comment in: Nature 1994; 370: 334.
166. Jameson BA, McDonnell JM, Marini JC, Korngold R. A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis [see comments]. Nature 1994; 368: 744-6. Comment in: Nature 1994; 368: 692-3, Comment in: Nature 1994; 370: 334.
167. Jameson BA, McDonnell JM, Marini JC, Korngold R. A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis [see comments]. Nature 1994; 368: 744-6. Comment in: Nature 1994; 368: 692-3, Comment in: Nature 1994; 370: 334.
168. Johns LD, Sriram S. Experimental allergic encephalomyelitis: Neutralizing antibody to TGF-β1 enhances the clinical severity of the disease. J Neuroimmunol 1993; 47: 1-7.
169. Johns LD, Flanders KC, Ranges GE, Sriram S. Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-β1. J Immunol 1991; 147: 1792-6.
170. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis. Results of a phase III multicenter, double-blind, placebo-controlled trial [see comments]. Neurology 1995; 45: 1268-76. Comment in: ]. Neurology 1995; 45: 1245-7.
171. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis. Results of a phase III multicenter, double-blind, placebo-controlled trial [see comments]. Neurology 1995; 45: 1268-76. Comment in: ]. Neurology 1995; 45: 1245-7.
172. Jung S, Toyka K, Hartung H-P. Suppression of experimental autoimmune encephalomyelitis in Lewis rats by antibodies against CD2. Eur J Immunol 1995; 25: 1391-8.
173. Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA. CTLA-4: a negative regulator of autoimmune disease. J Exp Med 1996; 184: 783-8.
174. Karin N, Mitchell DJ, Brocke S, Ling N, Steinman L. Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon-γ and tumor necrosis factor a production. J Exp Med 1994; 180: 2227-37.
175. Karpus WJ, Lukacs NW, McRae BL, Strieter RM, Kunkel SL, Miller SD. An important role for the chemokine macrophage inflammatory protein-1α in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol 1995; 155: 5003-10.
176. Karussis DM, Meiner Z, Lehmann D, Gomori J-M, Schwarz A, Linde A, et al. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide. Neurology 1996; 47: 341-6.
177. Kent SJ, Karlik SJ, Cannon C, Hines DK, Yednock TA, Fritz LC, et al. A monoclonal antibody to α4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol 1995; 58: 1-10.
178. Khoury SJ, Akalin E, Chandraker A, Turka LA, Linsley PS, Sayegh MH, et al. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol 1995; 155: 4521-4.
179. Khoury SJ, Gallon L, Verburg RR, Chandraker A, Peach R, Linsley PS, et al. Ex vivo treatment of antigen-presenting cells with CTLA4Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat. J Immunol 1996: 157: 3700-5.
180. Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti-TNF-α inhibitor: implications for clinical use. [Review]. Clin Immunol Immunopathol 1996; 81: 219-23.
181. Klinkert WEF, Kojima K, Lesslauer W, Rinner W, Lassmann H, Wekerle H. TNF-α receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview. J Neuroimmunol 1997; 72: 163-8.
182. Kojima K, Berger T, Lassmann H, Hinze-Seich D, Zhang Y, Gehrmann J, et al. Experimental autoimmune panencephalitis and uveoretinitis transferred to the Lewis rat by T lymphocytes specific for the S100β molecule, a calcium binding protein of astroglia. J Exp Med 1994; 180: 817-29.
183. Kotzin BL, Karuturi S, Chou YK, Lafferty J, Forrester JM, Better M, et al. Preferential T-cell receptor β-chain variable gene use in myelin basic protein-reactive T-cell clones from patients with multiple sclerosis. Proc Natl Acad Sci USA 1991; 88: 9161-5.
184. Kotzin BL, Leung DYM, Kappler J, Marrack P. Superantigens and their potential role in human disease. [Review]. Adv Immunol 1993; 54: 99-166.
185. Kramer R, Zhang Y, Gehrmann J, Gold R, Thoenen H, Wekerle H. Gene transfer through the blood-nerve barrier: nerve growth factor engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis. Nat Med 1995; 1: 1162-6.
186. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. [Review]. Trends Neurosci 1996; 19: 312-8.
187. Kuchroo VK, Greer JM, Kaul D, Ishioka G, Franco A, Sette A, et al. A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. J Immunol 1994; 153: 3326-36.
188. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, et al. B7-1 and B7-2 eostimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995; 80: 707-18.
189. KuruVilla AP, Shah R, Hochwald GM, Liggitt HD, Palladino MA, Thorbecke GJ. Protective effect of transforming growth factor β1 on experimental autoimmune diseases in mice. Proc Natl Acad Sci USA 1991; 88: 2918-21.
190. S molecules. J Immunol 1990; 145: 1687-3.
191. Lanzavecchia A. Identifying strategies for immune intervention. [Review]. Science 1993; 260: 937-44.
192. Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381:434-8.
193. Lassmann H, Vass K. Are current immunological concepts of multiple sclerosis reflected by the immunopathology of its lesions? [Review]. Springer Semin Immunopathol 1995; 17: 77-87.
194. Lassmann H, Rössler K, Zimprich F, Vass K. Expression of adhesion molecules and histocompatibility antigens at the blood-brain barrier. [Review]. Brain Pathol 1991a; 1: 115-23.
195. Lassmann H, Zimprich F, Rössler K, Vass K. Inflammation in the nervous system. Basic mechanisms and immunological concepts. [Review]. Rev Neurol (Paris) 1991b; 147: 763-81.
196. Lassmann H, Zimprich F, Vass K, Hickey WF. Microglial cells are a component of the perivascular glia limitans. J Neurosci Res 199Ic; 28: 236-43.
197. Lee S-W, Sullenger BA. Isolation of a nuclease-resistant decoy RNA that selectively blocks autoantibody binding to insulin receptors on human lymphocytes. J Exp Med 1996; 184: 315-24.
198. Lee JC, Laydon JT, McDonnell PCM, Gallagher TF, Kumar S, Green D, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994; 372: 739-46.
199. Legge KL, Min B, Potter NT, Zaghouani H. Presentation of a T cell receptor antagonist peptide by immunoglobulins ablates activation of T cells by a synthetic peptide or proteins requiring endocytic processing. J Exp Med 1997; 185: 1043-53.
200. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. [Review]. Annu Rev Immunol 1996; 14: 233-58.
201. Leonard JP, Waldburger KE, Goldman SJ. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med 1995; 181: 381-6.
202. Leppert D, Waubant E, Bürk MR, Oksenberg J, Hauser SL. IFN-β1b inhibits gelatinase secretion and in vitro migration of T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996; 40: 845-52.
203. + T cells in the pathogenesis of organ-specific autoimmune diseases [see comments]. [Review]. Immunol Today 1995; 16: 34-8.
204. Comment in: Immunol Today 1995; 16: 457-8.
205. Lindsey JW, Hodgkinson S, Mehta R, Mitchell D, Enzmann D, Steinman L. Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann Neurol 1994; 36: 183-9.
206. Ling PD, Warren MK, Vogel SN. Antagonistic effect of interferon-β on the nterferon-γ-induced expression of la antigen in murine macrophages. J Immunol 1985; 135: 1857-63.
207. Linington C, Bradl M, Lassmann H, Brunner C, Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 1988; 130: 443-54.
208. Linington C, Berger T, Perry L, Weerth S, Hinze-Selch D, Zhang Y, et al. T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system. Eur J Immunol 1993; 23: 1364-72.
209. Liu C, Goldstein J, Graziano RF, He J, O'Shea JK, Deo Y, et al. FcγRI-targeted fusion proteins result in efficient presentation by human monocytes of antigenic and antagonist T cell epitopes. J Clin Invest 1996a; 98: 2001-7.
210. Liu J, Zhao M-L, Brosnan CF, Lee SC. Expression of type II nitric oxide synthase in primary human astrocytes and microglia: role of IL-1β and IL-1 receptor antagonist. J Immunol 1996b; 157: 3569-76.
211. Lowenstein CJ, Snyder SH. Nitric oxide, a novel biologic messenger. [Review]. Cell 1992; 70: 705-7.
212. Lu H-T, Riley JL, Babcock GT, Huston M, Stark GR, Boss JM, et al. Interferon (IFN) β acts downstream of IFN-γ-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-γ. J Exp Med 1995; 182: 1517-25.
213. Lublin FD, Reingold SC, and the National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: relations between study investigators, advisors, and sponsors. [Review]. Neurology 1997; 48: 572-4.
214. Lucchinetti CF, Brück W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. [Review]. Brain Pathol 1996; 6: 259-74.
215. Lynch DH, Ramsdell F, Alderson MR. Fas and FasL in the homeostatic regulation of immune responses. [Review]. Immunol Today 1995; 16: 569-74.
216. Mackay CR. Chemokine receptors and T cell chemotaxis. [Review]. J Exp Med 1996; 184: 799-802.
217. Madden DR. The three-dimensional structure of peptide-MHC complexes. [Review]. Annu Rev Immunol 1995; 13: 587-622.
218. Maeda A, Sobel RA. Matrix metalloproteinases in the normal human central nervous system, microglial nodules and multiple sclerosis lesions. J Neuropathol Exp Neurol 1996; 55: 300-9.
219. Makarov SS, Olsen JC, Johnston WN, Anderle SK, Brown RR, Baldwin AS, et al. Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. Proc Natl Acad Sci USA 1996; 93: 402-6.
220. Mannie MD, Dinarello CA, Paterson PY. Interleukin 1 and myelin basic protein synergistically augment adoptive transfer activity of lymphocytes mediating experimental autoimmune encephalomyelitis in Lewis rats. J Immunol 1987; 138: 4229-35.
221. + T cell responses in experimental allergic encephalomyelitis. J Immunol 1996; 157: 3706-15.
222. Marks C, Marks JD. Phage libraries: a new route to clinically useful antibodies. N Engl J Med 1996; 335: 730-3.
223. Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives [published erratum appears in Science 1990; 248: 1066] [see comments]. [Review]. Science 1990; 248: 705-11. Comment in: Science 1990; 248: 685-6.
224. Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives [published erratum appears in Science 1990; 248: 1066] [see comments]. [Review]. Science 1990; 248: 705-11. Comment in: Science 1990; 248: 685-6.
225. Martin D, Near SL. Protective effect of the interleukin-1 receptor antagonist (IL-1ra) on experimental allergic encephalomyelitis in rats. J Neuroimmunol 1995; 61: 241-5.
226. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. [Review]. Annu Rev Immunol 1992; 10: 153-87.
227. Matsumoto Y, Fujiwara M. Adoptively transferred experimental allergic encephalomyelitis in chimeric rats: identification of transferred cells in the lesions of the central nervous system. Immunology 1988; 65: 23-9.
228. McDonald WI, Miller DH, Barnes D. The pathological evolution of multiple sclerosis. [Review]. Neuropathol Appl Neurobiol 1992; 18: 319-34.
229. McFarland HF. Complexities in the treatment of autoimmune disease [comment]. Science 1996; 274: 2037-8. Comment on: Science 1996; 274: 2054-7, Comment on: Science 1996; 274: 1707-9.
230. McFarland HF. Complexities in the treatment of autoimmune disease [comment]. Science 1996; 274: 2037-8. Comment on: Science 1996; 274: 2054-7, Comment on: Science 1996; 274: 1707-9.
231. McFarland HF. Complexities in the treatment of autoimmune disease [comment]. Science 1996; 274: 2037-8. Comment on: Science 1996; 274: 2054-7, Comment on: Science 1996; 274: 1707-9.
232. McGeehan GM, Becherer JD, Bast RC Jr, Boyer CM, Champion B, Connolly KM, et al. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature 1994; 370: 558-61.
233. McInnes IB, al-Mughales J, Field M, Leung BP, Huang F-P, Dixon R, et al. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med 1996; 2: 175-82.
234. McMorris FA, McKinnon RD. Regulation of oligodendrocyte development and CNS myelination by growth factors: prospects for therapy of demyelinating disease. [Review]. Brain Pathol 1996; 6: 313-29.
235. McMurray RW. Adhesion molecules in autoimmune diseases. [Review]. Seminars in Arthritis and Rheumatism. Arthritis Rheum 1996; 25: 215-33.
236. Medaer R, Stinissen P, Truyen L, Raus J, Zhang J. Depletion of myelin-basic protein autoreactive T cells by T-cell vaccination: pilot trial in multiple sclerosis. Lancet 1995; 346: 807-8.
237. Meinl E, Weber F, Drexler K, Morelle C, Ott M, Saruhan-Direskeneli G, et al, Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones. J Clin Invest 1993; 92: 2633-43.
238. Meinl E, Aloisi F, Ertl B, Weber F, de Waal Malefyt R, Wekerle H, et al. Multiple sclerosis: Immunomodulatory effects of human astrocytes on T cells. Brain 1994; 117: 1323-32.
239. Meinl E, Hoch RM, Dornmair K, de Waal Malefyt R, Bontrop RE, Jonker M, et al. Encephalitogenic potential of myelin-basic-protein-specific T cells isolated from normal rhesus macaques. Am J Pathol 1997. In press.
240. Metzler B, Wraith DC. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int Immunol 1993; 5: 1159-65.
241. Miller DH, Barkhof F, Nauta JJP. Gadolinium enhancement increases the sensitivity of MRI in detecting disease acitivity in multiple sclerosis. Brain 1993; 116: 1077-94.
242. Miller SD, McRae BL, Vanderlugt CL, Nikcevich KM, Pope JG, Pope L, et al. Evolution of the T-cell repertoire during the course of experimental immune-mediated demyelinating diseases. [Review]. Immunol Rev 1995a; 144: 225-44.
243. Miller SD, Vanderlugt C, Lenschow DJ, Pope JG, Karandikar NJ, Dal Canto MC, et al. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity 1995b; 3: 739-45.
244. Miller DH, Albert PS, Barkhof F, Francis G, Frank JA, Hodgkinson S, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996a; 39: 6-16.
245. Miller DJ, Asakura K, Rodriguez M. Central nervous system remyelination. Clinical application of basic neuroscience principles. [Review]. Brain Pathol 1996b; 6: 331-44.
246. Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Alderson M, Kerwar SS, et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 1994; 370: 218-20.
247. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. [Review]. Annu Rev Immunol 1993; 11: 165-90.
248. Moreau T, Coles A, Wing M, Isaacs J, Hale G, Waldmann H, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996; 119: 225-37.
249. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. [Review]. Immunol Today 1996; 17: 138-45.
250. Moss ML, Jin SLC, Milla ME, Burkhart W, Carter HL, Chen W-J, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 1997; 385: 733-6.
251. Murphy PM. The molecular biology of leukocyte chemoattractant receptors. [Review]. Annu Rev Immunol 1994; 12: 593-633.
252. Murphy E, Shibuya K, Hosken N, Openshaw P, Maino V, Davis K, et al. Reversibility of T helper 1 and 2 populations is lost after long-term stimulation. J Exp Med 1996; 183: 901-13.
253. Nagata S, Golstein P. The Fas death factor. [Review]. Science 1995; 267: 1449-56.
254. Nicholson LB, Greer JM, Sobel RA, Lees MB, Kuchroo VK. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 1995; 3: 397-405.
255. Noelle RJ. CD40 and its ligand in host defense. [Review]. Immunity 1996; 4: 415-9.
256. Nolte K-U, Günther G, von Wussow P. Epitopes recognized By neutralizing therapy-induced human anti-interferon-α antibodies are localized within the N-terminal functional domain of recombinant interferon-α2. Eur J Immunol 1996; 26: 2155-9.
257. Norga K, Paemen L, Masure S, Dillen C, Heremans H, Billiau A, et al. Prevention of acute autoimmune encephalomyelitis and abrogation of relapses in murine models of multiple sclerosis by the protease inhibitor D-penicillamine. Inflamm Res 1995; 44; 529-34.
258. Olsson T. Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis. [Review]. Immunol Rev 1995; 144: 245-68.
259. Ozawa K, Suchanek G, Breitschopf H, Brück W, Budka H, Jellinger K, et al. Patterns of oligodendroglia pathology in multiple sclerosis. Brain 1994; 117: 1311-22.
260. Padovan E, Casorati G, Dellabona P, Meyer S, Brockhaus M, Lanzavecchia A. Expression of two T cell receptor α chains: dual receptor T cells. Science 1993; 262: 422-4.
261. Padovan E, Giachino C, Cella M, Valitutti S, Acuto O, Lanzavecchia A. Normal T lymphocytes can express two different T cell receptor β chains: implications for the mechanism of allelic exclusion. J Exp Med 1995; 181: 1587-91.
262. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 1987; 37: 1097-102.
263. Pardoll DM, Beckerleg AM. Exposing the immunology of naked DNA vaccines. [Review]. Immunity 1995; 3: 165-9.
264. Paty DW, Li DKB, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial [see comments]. Neurology 1993; 43: 662-7. Comment in: Neurology 1993; 43: 641-3.
265. Paty DW, Li DKB, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial [see comments]. Neurology 1993; 43: 662-7. Comment in: Neurology 1993; 43: 641-3.
266. Paty DW, Goodkin D, Thompson A, Rice G. Guidelines for physicians with patients on IFNβ-1b: The use of an assay for neutralizing antibodies (NAB). Neurology 1996; 47: 865-6.
267. Paul WE. Pleiotropy and redundancy: T cell-derived lymphokines in the immune response. [Review]. Cell 1989; 57: 521-4.
268. Paul WE, Seder RA. Lymphocyte responses and cytokines. [Review]. Cell 1994; 76: 241-51.
269. Perrin PJ, Scott D, Quigley L, Albert PS, Feder O, Gray GS, et al. Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. J Immunol 1995; 154: 1481-90.
270. Perrin PJ, Scott D, Davis TA, Gray GS, Doggett MJ, Abe R, et al. Opposing effects of CTLA4-Ig and anti-CD80 (B7-1) plus anti-CD86 (B7-2) on experimental allergic encephalomyelitis. J Neuroimmunol 1996; 65: 31-9.
271. Perry VH, Andersson P-B, Gordon S. Macrophages and inflammation in the central nervous system. [Review]. Trends Neurosci 1993; 16: 268-73.
272. Petsko GA. For medicinal purposes [comment]. Nature 1996; 384 (Suppl): 7-9.
273. Piddlesden SJ, Storch MK, Hibbs M, Freeman AM, Lassmann H, Morgan BP. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J Immunol 1994; 152: 5477-84.
274. Polman CH, Hartung H-P. The treatment of multiple sclerosis: current and future. [Review]. Curr Opin Neurol 1995; 8: 200-9.
275. Powell MB, Mitchell D, Lederman J, Buckmeier J, Zamvil SS, Graham M, et al. Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int Immunol 1990; 2: 539-44.
276. Prineas JW. The neuropathology of multiple sclerosis. [Review]. In: Vinken PJ, Bruyn GW, Klawans HL, editors. Handbook of clinical neurology, Vol. 47. Amsterdam: Elsevier, 1985: 213-57.
277. Rabinowitz JD, Beeson C, Lyons DS, Davis MM, McConnell HM. Kinetic discrimination in T-cell activation. Proc Natl Acad Sci USA 1996; 93: 1401-5.
278. Racke MK, Dhib-Jalbut S, Cannella B, Albert PS, Raine CS, McFarlin DE. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β1. J Immunol 1991; 146: 3012-7.
279. Racke MK, Bonomo A, Scott DE, Cannella B, Levine A, Raine CS, et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med 1994; 180: 1961-6.
280. Racke MK, Scott DE, Quigley L, Gray GS, Abe R, June CH, et al. Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis. J Clin Invest 1995; 96: 2195-203.
281. Racke MK, Critchfield JM, Quigley L, Cannella B, Raine CS, McFarland HF, et al. Intravenous antigen administration as a therapy for autoimmune demyelinating disease. Ann Neurol 1996; 39: 46-56.
282. Raine CS. Demyelinating diseases. [Review]. In: Davis RL, Robertson DM, editors. 2nd ed. Textbook of Neuropathology. Baltimore: Williams & Wilkins, 1991: 535-620.
283. Raine CS. Multiple sclerosis: immune system molecule expression in the central nervous system. [Review]. J Neuropathol Exp Neurol 1994; 53: 328-37.
284. Raine CS, Lee SC, Scheinberg LC, Duijvestin AM, Cross AH. Adhesion molecules on endothelial cells in the central nervous system: an emerging area in the neuroimmunology of multiple sclerosis. [Review]. Clin Immunol Immunopathol 1990; 57: 173-87.
285. Raine CS, Wu E, Ivanyi J, Katz D, Brosnan CF. Multiple sclerosis: a protective or a pathogenic role for heat shock protein 60 in the central nervous system? Lab Invest 1996; 75: 109-23.
286. Ransohoff RM, Hamilton TA, Tani M, Stoler MH, Shick HE, Major JA, et al. Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis. FASEB J 1993; 7: 592-600.
287. Reder AT, Lowy MT. Interferon-β treatment does not elevate cortisol in multiple sclerosis. J Interferon Res 1992; 12: 195-8.
288. Redondo C, Flores I, Gonzales A, Nagata S, Carrera AC, Merida I, et al. Linomide prevents the lethal effect of anti-Fas antibody and reduces Fas-mediated ceramide production in mouse hepatocytes. J Clin Invest 1996; 98: 1245-52.
289. Rep MHG, Hintzen RQ, Polman CH, van Lier RAW. Recombinant interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J Neuroimmunol 1996; 67: 111-8.
290. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, et al. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology 1994; 44: 1523-6.
291. Rieckmann P, Michel U, Albrecht M, Brück W, Wöckel L, Felgenhauer K. Soluble forms of intercellular adhesion molecule-1 (ICAM-1) block lymphocyte attachment to cerebral endothelial cells. J Neuroimmunol 1995; 60: 9-15.
292. Rieckmann P, Weber F, Günther A, Martin S, Bitsch A, Broocks A, et al. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol 1996; 64: 193-200.
293. Röcken M, Racke M, Shevach EM. IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. [Review]. Immunol Today 1996; 17: 225-31.
294. Rodriguez M, Miller DJ, Lennon VA. Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology 1996; 46: 538-45.
295. Rogy MA, Auffenberg T, Espat NJ, Philip R, Remick D, Wollenberg GK, et al. Human tumor necrosis factor receptor (p55) and interleukin 10 gene transfer in the mouse reduces mortality to lethal endotoxemia and also attenuates local inflammatory responses. J Exp Med 1995; 181: 2289-93.
296. Rollwagen FM, Baqar S. Oral cytokine administration. [Review]. Immunol Today 1996; 17: 548-50.
297. Romagnani S. Lymphokine production by human T cells in disease states. [Review]. Annu Rev Immunol 1994; 12: 227-57.
298. Rothenberg EV. How T cells count, [comment]. Science 1996; 273: 78-4. Comment on: Science 1996; 273: 104-6
299. Rothenberg EV. How T cells count, [comment]. Science 1996; 273: 78-4. Comment on: Science 1996; 273: 104-6
300. Rott O, Fleischer B, Cash E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol 1994; 24: 1434-40.
301. Rowen L, Koop BF, Hood L. The complete 685-kilobase DNA sequence of the human β T cell receptor locus. Science 1996; 272: 1755-62.
302. Ruddle NH, Bergman CM, McGrath KM, Lingenheld EG, Grunnet ML, Padula SJ, et al. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 1990; 172: 1193-200.
303. Rudick RA, Ransohoff RM. Cytokine secretion by multiple sclerosis monocytes. Relationship to disease activity. Arch Neurol 1992; 49: 265-70.
304. Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, et al. Clinical outcomes assessment in multiple sclerosis. [Review]. Ann Neurol 1996a; 40: 469-79.
305. Rudick RA, Ransohoff RM, Peppler R, VanderBrug Medendorp S, Lehmann P, Alam J. Interferon beta induces interleukin-10 expression: Relevance to multiple sclerosis. Ann Neurol 1996b; 40: 618-27.
306. Ruoslahti E. Integrins. [Review]. J Clin Invest 1991; 87: 1-5.
307. Ruuls SR, de Labic MCDC, Weber KS, Botman CAD, Groenestein RJ, Dijkstra CD, et al. The length of treatment determines whether IFN-β prevents or aggravates experimental autoimmune encephalomyelitis in Lewis rats. J Immunol 1996; 157: 5721-31.
308. Samson MF, Smilek DE. Reversal of acute experimental autoimmune encephalomyelitis and prevention of relapses by treatment with a myelin basic protein peptide analogue modified to form long-lived peptide-MHC complexes. J Immunol 1995; 155: 2737-46.
309. Satoh J-I, Lee YB, Kim SU. T-cell costimulatory molecules B7-1 (CD80) and B7-2 (CD86) are expressed in human microglia but not in astrocytes in culture. Brain Res 1995; 704: 92-6.
310. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of IkBα in mediation of immunosuppression by glucocorticoids [see comments]. Science 1995; 270: 283-6. Comment in: Science 1995; 270: 232-3.
311. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of IkBα in mediation of immunosuppression by glucocorticoids [see comments]. Science 1995; 270: 283-6. Comment in: Science 1995; 270: 232-3.
312. Scherer MT, Ignatowicz L, Winslow GM, Kappler JW, Marrack P. Superantigens: bacterial and viral proteins that manipulate the immune system. [Review]. Annu Rev Cell Biol 1993; 9: 101-28.
313. Schluesener HJ, Lider O. Transforming growth factors β1 and β2: cytokines with identical immunosuppressive effects and a potential role in the regulation of autoimmune T cell function. J Neuroimmunol 1989; 24: 249-58.
314. Schluesener HJ, Wekerle H. Autoaggressive T lymphocyte lines recognizing the encephalitogenic region of myelin basic protein: in vitro selection from unprimed rat T lymphocyte populations. J Immunol 1985; 135: 3128-33.
315. Schwartz MA, Schaller MD, Ginsberg MH. Integrins: emerging paradigms of signal transduction. [Review]. Annu Rev Cell Biol 1995; 11: 549-99.
316. Schwrtz RH. Models of T cell anergy: Is there a common molecular mechanism? [comment]. [Review]. J Exp Med 1996: 184: 1-8. Comment on: J Exp Med 1996; 184: 19-29.
317. Schwrtz RH. Models of T cell anergy: Is there a common molecular mechanism? [comment]. [Review]. J Exp Med 1996: 184: 1-8. Comment on: J Exp Med 1996; 184: 19-29.
318. + T cells. [Review]. Annu Rev Immunol 1994; 12: 635-73.
319. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988; 23: 339-46.
320. + oligodendrocytes in multiple sclerosis. Proc Natl Acad Sci USA 1991a; 88: 6452-6.
321. Selmaj K, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991b; 87: 949-54.
322. Selmaj K, Raine CS, Farooq M, Norton WT, Brosnan CF. Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin. J Immunol 1991c; 147: 1522-9.
323. Selmaj K, Papierz W, Gfabinski A, Kohno T. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J Neuroimmunol 1995; 56: 135-41.
324. Sen GC, Ransohoff RM. Interferon-induced antiviral actions and their regulation. [Review]. Adv Virus Res 1993; 42: 57-102.
325. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Moudgil K, Dominance and crypticity of T cell antigenic determinants. [Review]. Annu Rev Immunol 1993; 11: 729-66.
326. Sharief MK, Hentges R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis [see comments], N Engl J Med 1991; 325: 467-72. Comment in: N Engl J Med 1992; 326: 272-3.
327. Sharief MK, Hentges R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis [see comments], N Engl J Med 1991; 325: 467-72. Comment in: N Engl J Med 1992; 326: 272-3.
328. Shrikant P, Benveniste EN, The central nervous system as an immunocompetent organ. Role of glial cells in antigen presentation. [Review]. J Immunol 1996; 157: 1819-22.
329. Sinha B, Semmler J, Eisenhut T, Eigler A, Endres S. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur J Immunol 1995; 25: 147-53.
330. Sloan-Lancaster J, Alien PM. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. [Review]. Annu Rev Immunol 1996; 14: 1-27.
331. Smilek DE, Wraith DC, Hodgkinson S, Dwivedy S, Steinman L, McDevitt HO. A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 1991; 88: 9633-7.
332. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death. [Review]. Cell 1994; 76: 959-62.
333. Sommer N, Löschmann P-A, Northoff GH, Weller M, Steinbrecher A, Steinbach JP, et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis [see comments]. Nat Med 1995; 1: 244-8. Comment in: Nat Med 1995; 1: 211-4.
334. Sommer N, Löschmann P-A, Northoff GH, Weller M, Steinbrecher A, Steinbach JP, et al. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis [see comments]. Nat Med 1995; 1: 244-8. Comment in: Nat Med 1995; 1: 211-4.
335. + T cells, analyzed at the single-cell level. J Exp Med 1996; 184: 473-83.
336. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. [Review]. Cell 1994; 76: 301-14.
337. Stavnezer J. Regulation of antibody production and class switching by TGF-β. [Review]. J Immunol 1995; 155: 1647-51.
338. Stein CA, Cheng Y-C. Antisense oligonucleotides as therapeutic agents-is the bullet really magical? [Review]. Science 1993; 261: 1004-12.
339. Steinman L. A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantry. [Review]. Proc Natl Acad Sci USA 1996; 93: 2253-6.
340. Steinman L, Rosenbaum JT, Sriram S, McDevitt HO. In vivo effects of antibodies to immune response gene products: Prevention of experimental allergic encephalitis. Proc Natl Acad Sci USA 1981; 78: 7111-4.
341. Steinman L, Waisman A, Altmann D. Major T-cell responses in multiple sclerosis. [Review]. Mol Med Today 1995; 1: 79-83.
342. Stevens DB, Gould KE, Swanborg RH. Transforming growth factor-β1 inhibits tumor necrosis factor-α/lymphotoxin production and adoptive transfer of disease by effector cells of autoimmune encephalomyelitis. J Neuroimmunol 1994; 51: 77-83.
343. St Louis J, Chan EL, Singh B, Strejan GH. Suppression of experimental allergic encephalomyelitis in the Lewis rat, by administration of an acetylated synthetic peptide of myelin basic protein. J Neuroimmunol 1997; 73: 90-100.
344. Stone LA, Frank JA, Albert PS, Bash C, Smith ME, Maloni H, et al. The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995; 37: 611-9.
345. Stüve O, Dooley NP, Uhm JH, Antel JP, Francis GS, Williams G, et al. Interferon beta 1-b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996; 40: 853-63.
346. + T line cells. Eur J Immunol 1988a; 18: 1993-9.
347. Sun D, Qin Y, Chluba J, Epplen JT, Wekerle H. Suppression of experimentally induced autoimmune encephalomyelitis by cytolytic T-T cell interactions. Nature 1988b; 332: 843-5.
348. Sun JB, Rask C, Olsson T, Holmgren J, Czerkinsky C. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc Natl Acad Sci USA 1996; 93: 7196-201.
349. Taniguchi T. Cytokine signaling through nonreceptor protein tyrosine kinases. [Review]. Science 1995; 268: 251-5.
350. Taub DD, Turcovski-Corrales SM, Key ML, Longo DL, Murphy WJ. Chemokines and T lymphocyte activation: I. β chemokines costimulate human T lymphocyte activation in vitro. J Immunol 1996; 156: 2095-103.
351. Teitelbaum D, Fridkis-Hareli M, Amon R, Sela M. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J Neuroimmunol 1996; 64: 209-17.
352. Thompson AJ, Noseworthy JH. New treatments for multiple sclerosis: a clinical perspective. [Review]. Curr Opin Neurol 1996; 9: 187-98.
353. Thompson AJ, Polman CH, Miller DH, Brochet B, Filippi M, Montalban K, et al. Primary progressive multiple sclerosis: a review. [Review]. Brain 1997. In press.
354. Thorpe JW, Kidd D, Moseley IF, Kenndall BE, Thompson AJ, MacManus DG, et al. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology 1996; 46: 373-8.
355. Thrush GR, Lark LR, Clinchy BC, Vitetta ES. Immunotoxins: an update. [Review]. Annu Rev Immunol 1996; 14: 49-71.
356. Torcia M, Bracci-Laudiero L, Lucibello M, Nencioni L, Labardi D, Rubartelli A, et al. Nerve growth factor is an autocrine survival factor for memory B lymphocytes. Cell 1996; 85: 345-56.
357. Tracey KJ, Cerami A. Tumor necrosis factor, other cytokines and disease. [Review]. Annu Rev Cell Biol 1993; 9: 317-43.
358. Trinchieri G, Perussia B. Immune Interferon: a pleiotropic lymphokine with multiple effects. [Review]. Immunol Today 1985; 6: 131-6.
359. Urban JL, Kumar V, Kono DH, Gomez C, Horvath SJ, Clayton J, et al. Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy. Cell 1988; 54: 577-92.
360. Vandenbark AA, Hashim G, Offner H. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 1989; 341: 541-4.
361. Vandenbark AA, Celnik B, Vainiene M, Miller SD, Offner H. Myelin antigen-coupled splenocytes suppress experimental autoimmune encephalomyelitis in Lewis rats through a partially reversible anergy mechanism. J Immunol 1995; 155: 5861-7.
362. Vandenbark AA, Chou YK, Whitham R, Mass M, Buenafe A, Liefeld D, et al. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat Med 1996a; 2: 1109-15.
363. Vandenbark AA, Hashim GA, Offner H. T cell receptor peptides in treatment of autoimmune disease: rationale and potential. [Review]. J Neurosci Res 1996b; 43: 391-402.
364. van Oosten BW, Lai M, Hodgkinson S, Barkhof F, Miller DH, Thompson AJ, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody Cm-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 1996a; 47: 1531-4.
365. van Oosten BW, Rep MHG, van Lier RAW, Scholten PET, von Blomberg BME, Pflughaupt KW, et al. A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis. J Neuroimmunol 1996b; 66: 49-55.
366. Vass K, Lassmann H. Intrathecal application of interferon gamma. Progressive appearance of MHC antigens within the rat nervous system. Am J Pathol 1990; 137: 789-800.
367. Vassalli P. The pathophysiology of tumor necrosis factors. [Review]. Annu Rev Immunol 1992; 10: 411-52.
368. Vaysburd M, Lock C, McDevitt H. Prevention of insulin-dependent diabetes mellitus in nonobese diabetic mice by immunogenic but not by tolerated peptides. J Exp Med 1995; 182: 897-902.
369. Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds [see comments]. Science 1996; 273: 104-6. Comment in: Science 1996; 273: 78-9.
370. Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds [see comments]. Science 1996; 273: 104-6. Comment in: Science 1996; 273: 78-9.
371. Wahl SM. Transforming growth factor β: the good, the bad, and the ugly. [Review]. J Exp Med 1994; 180: 1587-90.
372. Waisman A, Ruiz PJ, Hirschberg DL, Gelman A, Oksenberg JR, Brocke S, et al. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity [see comments]. Nat Med 1996; 2: 899-905. Comment in: ]. Nat Med 1996; 2: 857-9.
373. Waisman A, Ruiz PJ, Hirschberg DL, Gelman A, Oksenberg JR, Brocke S, et al. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity [see comments]. Nat Med 1996; 2: 899-905. Comment in: ]. Nat Med 1996; 2: 857-9.
374. Wauben MHM, Joosten I, Schlief A, van der Zee R, Boog CJP, van Eden W. Inhibition of experimental autoimmune encephalomyelitis by MHC class II binding competitor peptides depends on the relative MHC binding affinity of the disease-inducing peptide. J Immunol 1994; 152: 4211-20.
375. Weber F, Meinl E, Aloisi F, Nevinny-Stickel C, Albert E, Wekerle H, et al. Human astrocytes are only partially competent antigen presenting cells: possible implications for lesion development in multiple sclerosis. Brain 1994; 117: 59-69.
376. Weinberg AD, Bourdette DN, Sullivan TJ, Lemon M, Wallin JJ, Maziarz R, et al. Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat Med 1996; 2: 183-9.
377. Weiner HL, Mackin GA, Matsui M, Orav EJ, Khoury SJ, Dawson DM, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis [see comments]. Science 1993; 259: 1321-4. Comment in: Science 1993; 259: 1263.
378. Weiner HL, Mackin GA, Matsui M, Orav EJ, Khoury SJ, Dawson DM, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis [see comments]. Science 1993; 259: 1321-4. Comment in: Science 1993; 259: 1263.
379. Weiner HL, Friedman A, Miller A, Khoury SJ, al-Sabbagh A, Santos L, et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. [Review]. Annu Rev Immunol 1994; 12: 809-37.
380. Weinshenker BG, Bass B, Karlik S, Ebers GC, Rice GPA. An open trial of OKT3 in patients with multiple sclerosis. Neurology 1991; 41: 1047-52.
381. Weinstock-Guttman B, Ransohoff RM, Kinkel RP, Rudick RA. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. [Review]. Ann Neurol 1995; 37: 7-15.
382. Wekerle H. Antigen presentation by central nervous system glia. [Review]. In: Kettenmann H, Ransom B, editors. Neuroglial Cells. New York: Oxford University Press, 1995: 685-99.
383. Wekerle H, Linington C, Lassmann H, Meyermann R. Cellular immune reactivity within the CNS. [Review]. Trends Neurosci 1986; 9: 271-7.
384. Wekerle H, Kojima K, Lannes-Vieira J, Lassmann H, Linington C. Animal models. [Review]. Ann Neurol 1994; 36 Suppl: S47-53.
385. Wekerle H, Bradl M, Linington C, Kääb G, Kojima K. The shaping of the brain-specific T lymphocyte repertoire in the thymus. [Review]. Immunol Rev 1996; 149: 231-43.
386. Welsh CT, Rose JW, Hill KE, Townsend JJ. Augmentation of adoptively transferred experimental allergic encephalomyelitis by administration of a monoclonal antibody specific for LFA-1α. J Neuroimmunol 1993; 43: 161-7.
387. Whitaker JN, McFarland HF, Rudge R, Reingold SC. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. [Review]. Multiple Sclerosis 1995; 11: 37-47.
388. Williams K, Ulvestad E, Antel JP. B7/BB-1 antigen expression on adult human microglia studied in vitro and in situ. Eur J Immunol 1994; 24: 3031-7.
389. Williams LM, Gibbons DL, Gearing A, Maini RN, Feldmann M, Brennan FM. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF-α processing in RA synovial membrane cell cultures. J Clin Invest 1996; 97: 2833-41.
390. Windhagen A, Newcombe J, Dangond F, Strand C, Woodroofe MN, Cuzner ML, et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 1995a; 182: 1985-96.
391. Windhagen A, Scholz C, Höllsberg P, Fukaura H, Sette A, Hafler DA. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity 1995b; 2: 373-80.
392. Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology. [Review]. Annu Rev Immunol 1994; 12: 433-55.
393. Wolinsky JS. Copolymer 1: A most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disability [editorial comment] [see comments]. [Review]. Neurology 1995; 45; 1245-7. Comment on: Neurology 1995; 45: 1268-76, Comment in: Neurology 1996; 46: 883.
394. Wolinsky JS. Copolymer 1: A most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disability [editorial comment] [see comments]. [Review]. Neurology 1995; 45; 1245-7. Comment on: Neurology 1995; 45: 1268-76, Comment in: Neurology 1996; 46: 883.
395. Wolinsky JS. Copolymer 1: A most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disability [editorial comment] [see comments]. [Review]. Neurology 1995; 45; 1245-7. Comment on: Neurology 1995; 45: 1268-76, Comment in: Neurology 1996; 46: 883.
396. Wraith DC. Induction of antigen-specific unresponsiveness with synthetic peptides: specific immunotherapy for treatment of allergic and autoimmune conditions. [Review]. Int Arch Allergy Immunol 1995; 108: 355-9.
397. Wraith DC, McDevitt HO, Steinman L, Acha-Orbea H. T cell recognition as the target for immune intervention in autoimmune disease. [Review]. Cell 1989; 57: 709-15.
398. Wucherpfennig KW, Weiner HL, Hafler DA [see comments]. T-cell recognition of myelin basic protein [see comments]. [Review]. Immunol Today 1991; 12: 277-82. Comment in: Immunol Today 1991; 12: 464-5.
399. Wucherpfennig KW, Weiner HL, Hafler DA [see comments]. T-cell recognition of myelin basic protein [see comments]. [Review]. Immunol Today 1991; 12: 277-82. Comment in: Immunol Today 1991; 12: 464-5.
400. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995; 80: 695-705.
401. Xia M, Leppert D, Hauser SL, Sreedharan SP, Nelson PJ, Krensky AM, et al. Stimulus specificity of matrix metalloproteinase dependence of human T cell migration through a model basement membrane. J Immunol 1996; 156: 160-7.
402. Yednock TA, Cannon C, Fritz LC, Sánchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 1992; 356: 63-6.
403. Yin D, Fathman CG. Induction of tolerance to heart allografts in high responder rats by combining anti-CD4 with CTLA41g. J Immunol 1995; 155: 1655-9.
404. Yu M, Johnson JM, Tuohy VK. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. J Exp Med 1996a; 183: 1777-88.
405. Yu M, Nishiyama A, Trapp BD, Tuohy VK. Interferon-β inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J Neuroimmunol 1996b; 64: 91-100.
406. Yuen EC, Mobley WC. Therapeutic potential of neurotrophic factors for neurological disorders. [Review]. Ann Neurol 1996; 40: 346-54.
407. Zambidis ET, Scott DW. Epitope-specific tolerance induction with an engineered immunoglobulin. Proc Natl Acad Sci USA 1996; 93: 5019-24.
408. Zamvil SS, Mitchell DJ, Lee NE, Moore AC, Waldor MK, Sakai K, et al. Predominant expression of a T cell receptor Vβ gene subfamily in autoimmune encephalomyelitis [published erratum appears in J Exp Med 1988; 168: 455]. J Exp Med 1988; 167: 1586-96.
409. Zhang J, Vandevyver C, Stinissen P, Raus J. In vivo clonotypic regulation in human myelin basic protein-reactive T cells by T cell vaccination. J Immunol 1995; 155: 5868-77.
410. Zinkernagel RM, Doherty PC. The discovery of NHC restriction. [Review]. Immunol Today 1997; 18: 14-7.
411. Zipp F, Weber F, Huber S, Sotgiu S, Czlonkowska A, Holler E, et al. Genetic control of multiple sclerosis: increased production of lymphotoxin and tumor necrosis factor-alpha by HLA-DR2+ T cells [see comments]. Ann Neurol 1995; 38: 723-30. Comment in: Ann Neurol 1995; 38: 702-4.
412. Zipp F, Weber F, Huber S, Sotgiu S, Czlonkowska A, Holler E, et al. Genetic control of multiple sclerosis: increased production of lymphotoxin and tumor necrosis factor-alpha by HLA-DR2+ T cells [see comments]. Ann Neurol 1995; 38: 723-30. Comment in: Ann Neurol 1995; 38: 702-4.
413. Zurawski G, de Vries JE. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. [Review]. Immunol Today 1994; 15: 19-26.